Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RING1 and YY1-binding protein (RYBP) is a multifunctional nuclear protein that acts as a component and regulator of the Polycomb repressive complex 1 (PRC1). RYBP interacts directly with RING1A, RING1B, and transcription factor YY1, as well as the PcG protein M33, serving both as a structural element and an enzymatic stimulator within PRC1 complexes. It contains an N-terminal C2C2 zinc finger motif and is highly conserved with YAF2, another Polycomb group protein and YY1 interactor. RYBP's inclusion in PRC1 complexes increases the E3 ligase activity for histone H2A lysine 119 monoubiquitination (H2AK119ub1), thereby enhancing gene repression and contributing to the maintenance of chromatin structure. Loss or dysregulation of RYBP alters histone modification patterns and gene expression, resulting in chromatin domain erosion and has been implicated in cancer and potentially other developmental or neurodevelopmental disorders. RYBP also has known roles in apoptosis through interactions with death effector domain proteins and apoptin. It is not a direct receptor, enzyme, transporter, or ion channel, but rather a chromatin-associated regulatory protein that may serve as a therapeutic target in contexts where PRC1 function is aberrant. No approved drugs specifically target RYBP; rather, drug development efforts in chromatin biology and Polycomb complexes may indirectly affect its activity.
Modulation of Polycomb repressive complex 1 (PRC1) function; Stimulation of histone H2A ubiquitination (H2AK119ub1) via PRC1
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RING1 and YY1-binding protein (RYBP).